Australia : Valpam 5 (diazepam) 5 mg tablets - Product defect alert for potential for blister strip to contain lower strength tablets (English Only)
Therapeutic Goods Administration (TGA) announces that Arrow Pharma has issued a product defect alert for one batch of Valpam 5 due to the possibility of the blister strip including white Valpam 2 mg tablets, instead of yellow Valpam 5 mg tablets. 

A single Valpam 2 mg tablet was found in a blister pack of Valpam 5 mg tablets. 

The affected batch (numbered CP218) contains Valpam 5 mg tablet blister packs (50 tablets) with an expiry date of January 2021. 

The alert follows one instance where a single Valpam 2 mg tablet was found in a blister pack of Valpam 5 mg tablets from Batch CP218. No other batches are known to be affected. 

Arrow Pharma advises consumers and health professionals to visually inspect blisters from batch CP218 before dispensing or use, in order to ensure that all of the tablets in a given blister are coloured light yellow. The correct tablets should be marked with ‘DZ 5’ on one side, however this marking will only be visible on tablets that are loaded into the packaging with the numbered side facing the clear plastic blister. 

If a blister is found to contain a white or off-white tablet alongside the other yellow tablets, these blisters are affected and should not be used or supplied. 

Please refer to the following website in TGA for details: 

In Hong Kong, VALPAM 5 TAB 5MG (HK-50481) and VALPAM 2 TAB 2MG (HK-50482) are pharmaceutical products registered by Luen Cheong Hong Ltd. According to Luen Cheong Hong Ltd, the affected batch has not been imported into Hong Kong. 

Ends/ Wednesday, June 6, 2018 
Issued at HKT 17:45